ORIC · Oric Pharmaceuticals, Inc.
$13.91
+0.08 (+0.58%)
At close · Aug 26
Market Cap
$1.44B
Shares
103.65M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$129.47M
-1.3%
FY2025
Diluted EPS
-$1.47
+19.7%
FY2025
Operating Cash Flow
-$110.97M
+1.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $122.36M | $109.82M | $114.07M | $85.17M | $61.68M | $56.86M | $35.92M | $22.84M | $19.03M | |
| $33.78M | $33.19M | $28.82M | $25.61M | $25.09M | $22.01M | $13.42M | $5.73M | $3.35M | |
| $156.14M | $143M | $142.9M | $110.78M | $91.77M | $78.87M | $74.19M | $28.57M | $22.37M | |
| -$156.14M | -$143M | -$142.9M | -$110.78M | -$91.77M | -$78.87M | -$74.19M | -$28.57M | -$22.37M | |
| $15.79M | $13.54M | $15.05M | $10.08M | $2.65M | $156K | $483K | $1.69M | $1.01M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$140.35M | -$129.47M | -$127.85M | -$100.7M | -$89.12M | -$78.72M | -$73.7M | -$26.88M | -$21.36M | |
| -$141.56M | -$129.06M | -$127.73M | -$99.15M | -$90.31M | -$78.79M | -$73.73M | -$26.88M | -$21.36M | |
| USD/shares | — | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | — | — | — |
| USD/shares | — | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | — | — | — |
| shares | — | 87.79M | 69.73M | 51.45M | 39.66M | 37.95M | 21.94M | 1.9M | 1.73M |
| shares | — | 87.79M | 69.73M | 51.45M | 39.66M | 37.95M | 21.94M | 1.9M | 1.73M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.14×
EV/EBIT
—
Peer median 12.45×
P/E (TTM)
—
Peer median 17.78×
Peer medians compare against the 280 similar-size Biotechnology companies (of 534 listed).
Key facts
CIK
1796280
CUSIP
68622P109
13F (30d)
165 filings
165 filers
Visit website
Investor relations